EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Severe mold fungal infections in critically ill patients with COVID-19

Despoina Koulenti iD, Elisabeth Paramythiotou iD, Maria Panagiota Almyroudi iD, Marios Karvouniaris iD, Nikolaos Markou, Paschalis Paranos iD, Christina Routsi iD, Joseph Meletiadis, Stijn Blot iD

Future Microbiology · 2024

DOI: 10.2217/fmb-2023-0261 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Microbiology, 2024. Verfasst von Despoina Koulenti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, King's College Hospital NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: COVID-19, Critical Illness, Mucormycosis, Coinfection. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS-CoV-2 pandemic put an unprecedented strain on modern societies and healthcare systems. A significantly higher incidence of invasive fungal co-infections was noted compared with the pre-COVID-19 era, adding new diagnostic and therapeutic challenges in the critical care setting. In the current narrative review, we focus on invasive mold infections caused by Aspergillus and Mucor species in critically ill COVID-19 patients. We discuss up-to-date information on the incidence, pathogenesis, diagnosis and treatment of these mold-COVID-19 co-infections, as well as recommendations on preventive and prophylactic interventions. Traditional risk factors were often not recognized in COVID-19-associated aspergillosis and mucormycosis, highlighting the role of other determinant risk factors. The associated patient outcomes were worse compared with COVID-19 patients without mold co-infection. [Box: see text].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Critical IllnessMucormycosisCoinfectionSARS-CoV-2Invasive Fungal InfectionsHumansRisk FactorsAspergillusAspergillosisMucorAntifungal AgentsIncidence

Stichwörter der Autor:innen

CAMCAPACOVID-19antifungalsaspergillosiscritical illnessmoldsmucormycosis

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Department of Critical Care Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
  • Second Critical Care Department, Attikon University Hospital, Athens, Greece.
  • Emergency Department, Attikon University Hospital, National & Kapodistrian University of Athens, Greece.
  • Intensive Care Unit, AHEPA University Hospital, Thessaloniki, Greece.
  • Intensive Care Unit of Latseio Burns Centre, Thriasio General Hospital of Elefsina, Greece.

ORCID-Profile: Despoina Koulenti, Elisabeth Paramythiotou, Maria Panagiota Almyroudi, Marios Karvouniaris, Paschalis Paranos, Christina Routsi, Stijn Blot

Zitieren

APA

Koulenti, D., Paramythiotou, E., Almyroudi, M. P., Karvouniaris, M., Markou, N., Paranos, P., Routsi, C., Meletiadis, J., & Blot, S. (2024). Severe mold fungal infections in critically ill patients with COVID-19. Future Microbiology. https://doi.org/10.2217/fmb-2023-0261

Vancouver

Koulenti D, Paramythiotou E, Almyroudi MP, Karvouniaris M, Markou N, Paranos P, et al. Severe mold fungal infections in critically ill patients with COVID-19. Future Microbiology. 2024. doi:10.2217/fmb-2023-0261

BibTeX
@article{Koulenti2024,
  author = {Koulenti, Despoina and Paramythiotou, Elisabeth and Almyroudi, Maria Panagiota and Karvouniaris, Marios and Markou, Nikolaos and Paranos, Paschalis and Routsi, Christina and Meletiadis, Joseph and Blot, Stijn},
  title = {Severe mold fungal infections in critically ill patients with COVID-19},
  journal = {Future Microbiology},
  year = {2024},
  doi = {10.2217/fmb-2023-0261}
}
Kostenlos starten →